NCT07822542Not yet recruitingPhase 3
A Study Evaluating HS-10370 Plus Platinum-based Doublet Chemotherapy With or Without Adebrelimab vs. Tislelizumab Plus Chemotherapy as First-Line Therapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
A Randomized, Open-label, Controlled, Multicenter Phase 3 Trial of HS-10370 Plus Platinum-based Doublet Chemotherapy With or Without Adebrelimab vs. Tislelizumab Plus Chemotherapy as First-Line Therapy in Patients With Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation.
Source: ClinicalTrials.gov · Last updated 16 Sept 2026
Brief summary (registry, in English)
This is a trial to evaluate the efficacy, safety, and tolerability of HS-10370 in combination with Platinum-based Doublet Chemotherapy With or Without Adebrelimab Versus Tislelizumab Plus Platinum-based Doublet Chemotherapy as first-line treatment in participants with previously untreated, locally advanced or metastatic NSCLC with KRAS G12C mutation
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 448 (estimated)
- First submitted
- 11 Sept 2026
- Start date
- 31 Oct 2026
- Primary completion date
- 31 May 2030
- Lead sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
- Diseases
- Lung cancer
- NCT number
- NCT07822542
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 448
- From 31 Oct 2026 to the primary completion date, 31 May 2030
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Participants with tumors known to harbor molecular alterations for which targeted therapy is locally approved, except for KRAS G12C.
- Treatment with any of the following: Previous or current treatment with other KRAS G12C inhibitors.
Other illness
- History of other primary malignancies.
- Abnormal cardiac examination results.
- Severe, uncontrolled or active cardiovascular disorders.
- Uncontrolled hypertension.
- Severe bleeding symptoms or bleeding tendencies.
- Severe arteriovenous thrombosis occurred
- Serious infection.
- Active infectious diseases.
- Refractory nausea, vomiting, or chronic gastrointestinal diseases, or inability to swallow oral medications
- Interstitial lung disease (ILD).
- Serious neurological or mental disorders.
- Active autoimmune diseases.
Other
- Active brain metastases.
- Participants with uncontrolled pleural, ascites or pericardial effusion
- Continuous use of glucocorticoids
Who the study is looking for
- Participants are able to comply with the process of the protocol.
- Men or women greater than or equal to 18 years
- At least one measurable lesion in accordance with RECIST 1.1
- Must have an ECOG performance status of 0 or 1.
- Must have adequate laboratory parameters.
- Patients with advanced solid tumors who have failed after adequate standard treatment, are intolerant to standard treatment, or have no standard treatment available.
- Documentation of the presence of a KRAS G12C mutation
- Reproductive-age women agree to use adequate contraception and cannot breastfeed while participating in this study and for a period of 6 months after the last dose.Men also consent to use adequate contraceptive method within the same time limit.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.